Torrent expands recall of losartan products, again

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Zozulya)
(Image: Getty/Zozulya)

Related tags: Sartan, losartan, Torrent Pharmaceuticals, Hetero Labs, Recall

Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.

The recall was conducted in coordination with the US Food and Drug Administration (FDA), after finished product batches were manufactured with active pharmaceutical ingredient (API) produced by Hetero Labs – a company involved in previous recalls​.

Torrent Pharmaceuticals will recall three lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide tablets.

The recall was instigated after the impurity N-Methylnitrosobutyric acid (NMBA) was detected at levels above the acceptable daily intake levels, as specified by the FDA.

Torrent had previously recalled 104 lots​ of the same medicines, after NMBA was found in the API, also manufactured by Hetero.

In total, this is the sixth recall that Torrent has issued regarding losartan medications, which are used to treat hypertension and nephropathy in type 2 diabetic patients.

According to the company, it is arranging for a return of all recalled products and notifying its distributors and customers to immediately discontinue distribution of the affected lots.

The recall was announced amid a separate wave of recalls being made regarding potential contamination of ranitidine medicine, which resulted in Sandoz initiating a recall of its products​.

Related news

Show more

Related products

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more